Pituitary/growth disorders
NEWS
Researchers have identified novel pathogenic variants that may account for approximately 9% of children with Silver–Russell syndrome who have not previously had a molecular diagnosis and aid understanding of the relationships between genotype and phenotype.
One-year findings from the REAL5 trial show a continued growth response with use of long-acting human growth hormone treatment with somapacitan at a dose of 0.24 mg/kg per week in children born small for gestational age.
Central congenital hypothyroidism is frequently missed in Israeli infants despite a newborn screening programme for thyroid dysfunction, shows research published in the Journal of Clinical Endocrinology & Metabolism.
Italian researchers have determined a glucagon stimulation test threshold that can predict whether a teenager with growth hormone deficiency has or has not experienced normalisation of GH levels at the time of transition to adult care.
In depth
In our latest expert review, Afiya Andrews outlines the broad phenotypic spectrum of classical and non-classical growth hormone insensitivity disorders in children.
We are excited to welcome you to the Insights into MAnaging Growth for Endocrine nurses (IMAGE) June 2025 Meeting, organised by Springer Healthcare IME. This event will take place on 5–6 June 2025 in the vibrant city of Lisbon in Portugal.
A 12-year-old boy with a diagnosis of Carney Complex (CC) has accelerated growth. How does the endocrinologist manage this patient?
The Insights into MAnaging Growth for Endocrine nurses (IMAGE) March 2024 Meeting, organised by Springer Healthcare IME, provides high-quality, practical clinical training for nurses involved in paediatric endocrinology practice.
